Machado-Duque Manuel E, Gaviria-Mendoza Andrés, Valladales-Restrepo Luis F, Sebastián Franco Juan, Forero María de Rosario, Vizcaya David, Machado-Alba Jorge E
Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia. Universidad Tecnológica de Pereira - Audifarma S.A. Pereira, Colombia.
Grupo de investigación Biomedicina. Institución Universitaria Visión de las Américas, Pereira, Colombia.
PLoS One. 2025 Jun 24;20(6):e0325515. doi: 10.1371/journal.pone.0325515. eCollection 2025.
Heart failure is a common condition associated with significant mortality. Objective: to determine the prescription patterns of medications for the treatment of heart failure in a cohort of patients from Colombia.
This was a retrospective study based on the clinical records of patients diagnosed with heart failure between 2019 and 2020. Sociodemographic, clinical, paraclinical, and pharmacological variables and the specialty of the treating physician were identified. Patients were classified according to functional class, stage, and left ventricular ejection fraction (LVEF).
A total of 4742 patients were evaluated, with a mean age of 68.2 ± 13.8 years and a male predominance (61.3%). A total of 92.0% were classified as stage C and 54.8% as functional class I, the mean LVEF was 42.9 ± 14.8%, and 32.53% had reduced LVEF. 30.7% did not have LVEF data. The most common causes were ischemic heart disease (44.0%) and arterial hypertension (29.7%). A total of 5.2% had hospitalizations for heart failure in the last year, and 75.6% were attended by a general practitioner. These patients were treated with β-blockers (88.3%), renin-angiotensin-aldosterone system inhibitors (RAASis) (83.1%), loop diuretics (46.8%), and mineralocorticoid receptor antagonists (MRAs) (46.5%). Triple therapy with RAASis + β-blockers+MRAs was received by 56.4% of patients with reduced LVEF, 32.8% with mildly reduced LVEF and19.5% with preserved LVEF, while quadruple therapy adding a sodium-glucose cotransporter-2 inhibitor (SGLT2i) was given just to 4.6% with reduced LVEF.
The treatment that patients with heart failure with preserved LVEF is relatively simpler and is closer to the recommendations, while the proportion of indicated therapies according to guidelines is lower among those with reduced LVEF.
心力衰竭是一种常见疾病，死亡率很高。目的：确定哥伦比亚一组心力衰竭患者的药物治疗处方模式。
这是一项基于2019年至2020年期间确诊为心力衰竭患者临床记录的回顾性研究。确定了社会人口统计学、临床、辅助临床和药理学变量以及治疗医生的专业。根据功能分级、分期和左心室射血分数（LVEF）对患者进行分类。
共评估了4742例患者，平均年龄为68.2±13.8岁，男性占主导（61.3%）。92.0%被归类为C期，54.8%为功能I级，平均LVEF为42.9±14.8%，32.53%的患者LVEF降低。30.7%没有LVEF数据。最常见的病因是缺血性心脏病（44.0%）和动脉高血压（29.7%）。去年共有5.2%的患者因心力衰竭住院，75.6%由全科医生诊治。这些患者接受了β受体阻滞剂（88.3%）、肾素-血管紧张素-醛固酮系统抑制剂（RAASis）（83.1%）以及袢利尿剂（46.8%）和盐皮质激素受体拮抗剂（MRAs）（46.5%）治疗。LVEF降低的患者中有56.4%接受了RAASis+β受体阻滞剂+MRAs三联疗法，LVEF轻度降低的患者中有32.8%接受了该疗法，LVEF保留的患者中有19.5%接受了该疗法，而仅4.6%LVEF降低的患者接受了添加钠-葡萄糖协同转运蛋白-2抑制剂（SGLT2i）的四联疗法。
LVEF保留的心力衰竭患者的治疗相对简单，更接近推荐方案，而LVEF降低的患者中符合指南的指定治疗比例较低。
